Therapeutic siRNA for drug-resistant HER2-positive breast cancer

HER2 is overexpressed in about 20% of breast cancers and contributes to poor prognosis. Unfortunately, a large fraction of patients have primary or acquired resistance to the HER2-targeted therapy trastuzumab, thus a multi-drug combination is utilized in the clinic, putting significant burden on pat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Gu, Shenda, Hu, Zhi, Ngamcherdtrakul, Worapol, Castro, David J., Morry, Jingga, Reda, Moataz M., Gray, Joe W., Yantasee, Wassana
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4924747/
https://ncbi.nlm.nih.gov/pubmed/26894975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7409
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars